In April 2007, Morphotek Inc was acquired by Japanese firm Eisai Co., Ltd in all all cash transaction and now operates as a wholly owned subsiduary of Easai though - from listed post acqusition transactions - with some degree of automony in the acquired firm's areas of specialty. A global health care pharmaceutical company, one of Eisais areas of focus is oncology positioning the firm well to market oncology products developed by Morphotek. Morphotek, Inc., a biopharmaceutical company, had been engaging in the discovery and development of therapeutic monoclonal antibodies for the treatment of cancer, inflammatory, and infectious diseases. The companys products had relevance to treatment of ovarian cancer, endometrial cancer, renal carcinoma, non-small cell lung cancer, colo-rectal cancer, breast cancer, neovascular disease, other cancer types, pancreatic cancer, mesothelioma, rheumatoid arthritis, multiple sclerosis, asthma, and metastatic melanoma. The firm also develops libraries of antibody producing human hybridoma
